AbbVie (ABBV) announced Thursday morning that its Phase 2b study of upadacitinib met the primary endpoint and all skin and itch-specific secondary endpoints.
AbbVie climbed throughout the first half of Thursday's session, before settling into a range. The stock closed up by 4.73 at $81.78 with volume at nearly a 10-month high. AbbVie has been climbing for over 2 weeks and surged to a new high for the year.
For comments and feedback: editorial@rttnews.com